Journal
CANCER SCIENCE
Volume 113, Issue 11, Pages 3814-3825Publisher
WILEY
DOI: 10.1111/cas.15506
Keywords
biobank; leukemia; pediatric; preclinical; xenograft
Categories
Funding
- Kyoto preventive medical center
- Takeda Science Foundation
Ask authors/readers for more resources
A lack of practical resources in Japan has hindered preclinical discovery and testing of therapies for pediatric relapsed and refractory acute lymphoblastic leukemia (ALL). In this study, a PDX biobank was established, consisting of 57 patient-derived xenografts in mice, to mimic the biological features and treatment-mediated clonal selection of relapsed ALL. This biobank provides a valuable scientific resource for capturing drug sensitivity features of pediatric patients with ALL and aids in the development of targeted therapies.
A lack of practical resources in Japan has limited preclinical discovery and testing of therapies for pediatric relapsed and refractory acute lymphoblastic leukemia (ALL), which has poor outcomes. Here, we established 57 patient-derived xenografts (PDXs) in NOD.Cg-Prkdc(scid)ll2rg(tm1Sug)/ShiJic (NOG) mice and created a biobank by preserving PDX cells including three extramedullary relapsed ALL PDXs. We demonstrated that our PDX mice and PDX cells mimicked the biological features of relapsed ALL and that PDX models reproduced treatment-mediated clonal selection. Our PDX biobank is a useful scientific resource for capturing drug sensitivity features of pediatric patients with ALL, providing an essential tool for the development of targeted therapies.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available